MedPath

Oral Ivermectin Versus Topical Permethrin to Treat Scabies in Children and Adults

Phase 3
Completed
Conditions
Scabies
Interventions
Registration Number
NCT02407782
Lead Sponsor
University Hospital, Bordeaux
Brief Summary

Scabies remains a frequent condition that affects adults and children. The aim of this study is to compare the efficacy and safety of two drug treatments against scabies in children and their close contacts. One group will apply topical permethrin 5% and the other group will receive oral ivermectin.

Both groups will be treated twice, once at inclusion and the second time 10 days later. Both treatment regimens have been used widely and are safe to use.

Detailed Description

Scabies is a common condition, even in European countries, and the annual incidence seems to have increased over the past several years.

Children and infants represent one-third of patients with scabies. Diagnostic features comprise pruritus, skin burrows and the delta jet wing dermoscopic sign.

In many countries, topical permethrin is the first line therapy. Moreover, oral treatment with ivermectin represents an interesting alternative therapy, usually used as one dose of 200μg/kg, and more and more frequently recommended as two doses (one on day 1 and one between day 8 and day 15) without strong evidence. Management of scabies requires giving a treatment not only to the patient but also to the patient's close contacts.

The objective of our study is to compare efficacy and safety of topical permethrin applied twice at day 1 and day 10 versus oral ivermectin given twice at day 1 and day 10 to treat scabies in children and their close contacts. Children (2 to15 years) with scabies and their close contacts - or first circle- will be randomized 1:1 to receive permethrin or ivermectin.

A clinical follow-up will be performed 28 days (V2) and 56 days (V3) after the inclusion, including a dermatological examination and to collect safety data.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1092
Inclusion Criteria
  • children or adult
  • For children, weight more than 15 kg
  • Documented diagnosis of scabies, defined by positive dermoscopic examination.
Exclusion Criteria
  • Previous scabies therapy during the past 4 weeks
  • Known allergy to ivermectin or permethrin
  • Widespread eczematization or impetiginization
  • Liver or renal failure

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
IvermectinIvermectin-
PermethrinPermethrin-
Primary Outcome Measures
NameTimeMethod
Assessment of skin lesions and healing at day 28Day 28

Healing of skin lesions and disappearance of pruritus at day 28 of the treatment in the cluster composed by the child and its close contacts

Secondary Outcome Measures
NameTimeMethod
Number of unaffected members in clusters treated by permethrin versus ivermectin at D0, D28 and D56.day 0, day 28 and d56
Assessment of skin lesions and healing at day 56day 56

Healing of skin lesions and disappearance of pruritus at day 56 of the treatment in the cluster composed by the child and its close contacts.

Evaluation of delta wing jet sign(s) and mite egsDay 56
Assessment of skin lesions and healing at day 28 and 56 in childrenDay 28 and Day 56

Healing of skin lesions and disappearance of pruritus at day 28 and day 56 of the treatment in children

Incidence of serious adverse eventsDay 56

Safety in both groups

adherence of patientsDay 56

Preference and adherence of patients in both groups

Trial Locations

Locations (29)

CHU de Bordeaux Hôpital Pellegrin

🇫🇷

Bordeaux, Aquitaine, France

CHG de Chalon sur Saône

🇫🇷

Chalon sur Saône, Bourgogne, France

CHU de Dijon

🇫🇷

Dijon, Bourgogne, France

CHU de Rennes

🇫🇷

Rennes, Bretagne, France

CHRU de Tours

🇫🇷

Tours, Centre-Val De Loire, France

CH d'Argenteuil

🇫🇷

Argenteuil, ILE DE France, France

CHU de Créteil - Hôpital Henry Mondor

🇫🇷

Créteil, ILE DE France, France

AP-HP - Hôpital Robert Debré

🇫🇷

Paris, Ile De France, France

CHU de Montpellier

🇫🇷

Montpellier, Languedoc-Roussillon, France

CHU de la Réunion

🇫🇷

Saint-Pierre, Martinique, France

Scroll for more (19 remaining)
CHU de Bordeaux Hôpital Pellegrin
🇫🇷Bordeaux, Aquitaine, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.